Biotron appoints Glenn Gilbert as new CEO
- Biotron has appointed healthcare executive Glenn Gilbert as CEO and executive director, effective Jan 18, 2027.
- Following the announcement, the Biotron share price was unchanged at $0.002.
- The leadership transition is aimed at driving clinical development, regulatory execution, and commercialisation to unlock shareholder value.
Biotron (ASX:BIT) has appointed healthcare executive Glenn Gilbert as CEO and executive director, effective Jan 18, 2027, to lead its commercialisation strategy.
The leadership change comes as the clinical-stage biotechnology company continues progress on its ongoing research and development programmes.
Under the leadership agreement, Gilbert’s remuneration package features a reduced cash salary component offset by an equity structure aligned with long-term shareholder value creation.
Gilbert brings over 20 years of international healthcare experience across pharmaceuticals, medical devices, and in-vitro diagnostics to the role.
Following the announcement, the Biotron share price was unchanged at $0.002.
Prior to joining the company, Gilbert served as CEO of public unlisted firm Inspiring Holdings and held top leadership roles at ASX-listed companies Rhythm Biosciences (ASX:RHY) and Medical Developments International (ASX:MVP).
